• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page
Interesting Myeloma Articles September 2021

Interesting Myeloma Articles September 2021

by MM360 Staff | Sep 28, 2021 | Featured News, Myeloma News

Here are some interesting Myeloma journal articles and some of the most discussed on Twitter for September 2021. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to whites: a propensity-score...

Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse

by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News

People with blood type O are significantly less likely to develop multiple myeloma, but those who do are likely to have more aggressive disease and poorer survival outcomes, a study found. The study, “Effect of the ABO blood groups on the development, clinical...

Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients

by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News

The Israeli Ministry of Health has approved Xpovio (selinexor), in combination with the corticosteroid dexamethasone, for the treatment of people with multiple myeloma who have received three or more prior therapies, and who failed to respond to at least one...
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma

Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma

by MM360 Staff | Apr 21, 2021 | Featured, Webinars

Downloadable Slide Set In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient’s perspective on treatment options. Learners will also get a look ahead at emerging therapeutic...
Best Treatment for Newly Diagnosed Multiple Myeloma

Best Treatment for Newly Diagnosed Multiple Myeloma

by MM360 Staff | Apr 2, 2021 | Featured News, Myeloma News

A recent article published in JAMA Oncology1 questions whether VRd should remain as the standard of care (SOC) in newly diagnosed multiple myeloma. Careful analysis of the ENDURANCE (E1A11) phase III trial2 raises the question whether VRd continues to be the SOC for...
« Older Entries

Recent Content

  • Asembia AXS25: Cell and Gene Therapies Enter New Phase of Growth in Specialty Pharmacy
  • Asembia AXS25: Pharmacists Continue to Expand Clinical, Collaborative Role in Health Care
  • Asembia AXS25: Navigating Challenges in Cell and Gene Therapy
  • Targeted Therapies Transform CLL Care: Inside the Era of BTK and BCL-2 Inhibitors
  • Asembia AXS25: Pharmacy Perspectives on the Inflation Reduction Act
  • An AI-Driven Companion Diagnostic Receives FDA Designation in NSCLC
  • AACR 2025: Orally Bioavailable RIPTAC Therapeutic Targets p53-Y220C Mutant Tumors for Selective Cancer Cell Death
  • Investigating the Addition of Surgery to ICI Therapy in Kidney Cancer
  • Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
  • TAR-200 Shows High Response Rates in Bladder Cancer Subset
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT